Ionis Pharmaceuticals, Inc. (IONS) News

Ionis Pharmaceuticals, Inc. (IONS): $42.03

0.52 (-1.22%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add IONS to Watchlist
Sign Up

Filter IONS News Items

IONS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IONS News Highlights

  • IONS's 30 day story count now stands at 9.
  • Over the past 17 days, the trend for IONS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG, GENE and HAE are the most mentioned tickers in articles about IONS.

Latest IONS News From Around the Web

Below are the latest news stories about IONIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IONS as an investment opportunity.

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies

These future trillion dollar stocks can solidify portfolio growth for long-term investors.

William Cao on InvestorPlace | December 28, 2023

Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares

Ionis Pharmaceuticals Inc (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, has experienced a recent insider sell according to a SEC Filing.

Yahoo | December 24, 2023

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.

Yahoo | December 21, 2023

CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug

The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally. Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues.

Yahoo | December 21, 2023

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […]

Yahoo | December 20, 2023

Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.

Yahoo | December 20, 2023

Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Yahoo | December 19, 2023

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE). Ionis will maintain responsibility for the non-clinical and clinical development of donidalorsen, and Otsuka will be responsible for European regulatory filings and commercialization.

Yahoo | December 18, 2023

Ionis announces the appointment of Michael Yang to Board of Directors

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10.

Yahoo | December 14, 2023

Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!